ES2542511T3 - Expresión génica y dolor - Google Patents

Expresión génica y dolor Download PDF

Info

Publication number: ES2542511T3
Authority: ES; Spain
Prior art keywords: seq; decoy; sequence; nucleotide; oligonucleotide
Prior art date: 2007-05-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES08755344.2T

Other languages

English (en)

Spanish (es)

Inventor

Julien Mamet

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Adynxx Inc

Original Assignee

Adynxx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-05-11

Filing date

2008-05-12

Publication date

2015-08-06

2008-05-12 Application filed by Adynxx Inc filed Critical Adynxx Inc

2015-08-06 Application granted granted Critical

2015-08-06 Publication of ES2542511T3 publication Critical patent/ES2542511T3/es

Status Active legal-status Critical Current

2028-05-12 Anticipated expiration legal-status Critical

Links

208000002193 Pain Diseases 0.000 title claims description 123
230000036407 pain Effects 0.000 title claims description 114
230000014509 gene expression Effects 0.000 title description 82
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 549
102000040945 Transcription factor Human genes 0.000 claims abstract description 180
108091023040 Transcription factor Proteins 0.000 claims abstract description 180
230000027455 binding Effects 0.000 claims abstract description 111
238000009739 binding Methods 0.000 claims abstract description 109
210000004027 cell Anatomy 0.000 claims description 99
108090000623 proteins and genes Proteins 0.000 claims description 79
101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims description 57
102100023226 Early growth response protein 1 Human genes 0.000 claims description 51
238000000034 method Methods 0.000 claims description 46
239000008194 pharmaceutical composition Substances 0.000 claims description 37
230000008055 nociceptive signaling Effects 0.000 claims description 29
-1 IKZF Proteins 0.000 claims description 28
108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims description 20
102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims description 20
238000013518 transcription Methods 0.000 claims description 18
230000035897 transcription Effects 0.000 claims description 18
108010042291 Serum Response Factor Proteins 0.000 claims description 14
101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 claims description 12
101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 claims description 11
101000653735 Homo sapiens Transcriptional enhancer factor TEF-1 Proteins 0.000 claims description 11
102100020677 Krueppel-like factor 4 Human genes 0.000 claims description 11
102100035251 Protein C-ets-1 Human genes 0.000 claims description 11
102100022056 Serum response factor Human genes 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 10
210000002540 macrophage Anatomy 0.000 claims description 10
102100032057 ETS domain-containing protein Elk-1 Human genes 0.000 claims description 9
101000726098 Homo sapiens Calsenilin Proteins 0.000 claims description 9
101001139117 Homo sapiens Krueppel-like factor 7 Proteins 0.000 claims description 9
101001094741 Homo sapiens POU domain, class 4, transcription factor 1 Proteins 0.000 claims description 9
101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims description 9
101000881764 Homo sapiens Transcription elongation factor 1 homolog Proteins 0.000 claims description 9
101000744900 Homo sapiens Zinc finger homeobox protein 3 Proteins 0.000 claims description 9
101710163352 Potassium voltage-gated channel subfamily H member 4 Proteins 0.000 claims description 9
102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims description 9
101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims description 9
102100039966 Zinc finger homeobox protein 3 Human genes 0.000 claims description 9
101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 claims description 8
101001096159 Homo sapiens Pituitary-specific positive transcription factor 1 Proteins 0.000 claims description 8
102100037914 Pituitary-specific positive transcription factor 1 Human genes 0.000 claims description 8
208000004550 Postoperative Pain Diseases 0.000 claims description 8
102100040296 TATA-box-binding protein Human genes 0.000 claims description 8
101710145783 TATA-box-binding protein Proteins 0.000 claims description 8
102100031690 Erythroid transcription factor Human genes 0.000 claims description 7
101000914063 Eucalyptus globulus Leafy/floricaula homolog FL1 Proteins 0.000 claims description 7
101000877395 Homo sapiens ETS-related transcription factor Elf-1 Proteins 0.000 claims description 7
101001066268 Homo sapiens Erythroid transcription factor Proteins 0.000 claims description 7
101100456626 Homo sapiens MEF2A gene Proteins 0.000 claims description 7
101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 7
102000043138 IRF family Human genes 0.000 claims description 7
108091054729 IRF family Proteins 0.000 claims description 7
102100020692 Krueppel-like factor 7 Human genes 0.000 claims description 7
101100079042 Mus musculus Myef2 gene Proteins 0.000 claims description 7
102100021148 Myocyte-specific enhancer factor 2A Human genes 0.000 claims description 7
102100035395 POU domain, class 4, transcription factor 1 Human genes 0.000 claims description 7
102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 claims description 7
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 7
101710156592 Putative TATA-binding protein pB263R Proteins 0.000 claims description 7
102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 claims description 7
101150014102 mef-2 gene Proteins 0.000 claims description 7
102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 claims description 6
230000001105 regulatory effect Effects 0.000 claims description 6
102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims description 5
102100027313 Calsenilin Human genes 0.000 claims description 3
102100035075 ETS-related transcription factor Elf-1 Human genes 0.000 claims 1
108010086512 Hepatocyte Nuclear Factor 1 Proteins 0.000 claims 1
102000006754 Hepatocyte Nuclear Factor 1 Human genes 0.000 claims 1
101000805921 Strongylocentrotus purpuratus Upstream stimulatory factor Proteins 0.000 claims 1
102100040105 Upstream stimulatory factor 1 Human genes 0.000 claims 1
101000671634 Xenopus borealis Upstream stimulatory factor 1 Proteins 0.000 claims 1
239000010438 granite Substances 0.000 claims 1
239000002773 nucleotide Substances 0.000 description 326
125000003729 nucleotide group Chemical group 0.000 description 326
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 207
108020004414 DNA Proteins 0.000 description 142
238000012217 deletion Methods 0.000 description 92
230000037430 deletion Effects 0.000 description 92
238000011282 treatment Methods 0.000 description 70
230000000295 complement effect Effects 0.000 description 59
GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 46
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 46
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 46
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 46
230000005764 inhibitory process Effects 0.000 description 40
230000000694 effects Effects 0.000 description 34
150000001875 compounds Chemical class 0.000 description 33
102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 description 28
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 28
108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 description 28
230000033228 biological regulation Effects 0.000 description 27
238000002474 experimental method Methods 0.000 description 25
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
238000001890 transfection Methods 0.000 description 23
239000002585 base Substances 0.000 description 19
239000000203 mixture Substances 0.000 description 19
102100023995 Beta-nerve growth factor Human genes 0.000 description 18
108010025020 Nerve Growth Factor Proteins 0.000 description 18
108020004999 messenger RNA Proteins 0.000 description 18
210000002569 neuron Anatomy 0.000 description 18
102000005869 Activating Transcription Factors Human genes 0.000 description 17
238000002965 ELISA Methods 0.000 description 17
201000010099 disease Diseases 0.000 description 17
239000000523 sample Substances 0.000 description 16
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
235000018102 proteins Nutrition 0.000 description 15
102000004169 proteins and genes Human genes 0.000 description 15
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 14
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 14
101150080511 Scn9a gene Proteins 0.000 description 13
238000001514 detection method Methods 0.000 description 13
238000009396 hybridization Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 11
GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 11
229960005084 calcitriol Drugs 0.000 description 11
239000003814 drug Substances 0.000 description 11
150000003839 salts Chemical class 0.000 description 11
241000282414 Homo sapiens Species 0.000 description 10
101001045751 Homo sapiens Hepatocyte nuclear factor 1-alpha Proteins 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
241000700159 Rattus Species 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 9
229940088598 enzyme Drugs 0.000 description 9
210000003714 granulocyte Anatomy 0.000 description 9
239000000463 material Substances 0.000 description 9
239000002858 neurotransmitter agent Substances 0.000 description 9
230000035945 sensitivity Effects 0.000 description 9
210000003594 spinal ganglia Anatomy 0.000 description 9
208000004454 Hyperalgesia Diseases 0.000 description 8
101150043994 NOS1 gene Proteins 0.000 description 8
239000011543 agarose gel Substances 0.000 description 8
239000000284 extract Substances 0.000 description 8
239000007788 liquid Substances 0.000 description 8
150000007523 nucleic acids Chemical class 0.000 description 8
230000002265 prevention Effects 0.000 description 8
230000011664 signaling Effects 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 7
101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 7
101150112014 Gapdh gene Proteins 0.000 description 7
102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
239000002131 composite material Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
238000009472 formulation Methods 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
102000039446 nucleic acids Human genes 0.000 description 7
108020004707 nucleic acids Proteins 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
101150058477 Cdk5r1 gene Proteins 0.000 description 6
101150004665 GCH1 gene Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
101000995046 Homo sapiens Nuclear transcription factor Y subunit alpha Proteins 0.000 description 6
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 6
101150021841 Pnmt gene Proteins 0.000 description 6
102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 6
230000004913 activation Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
239000000499 gel Substances 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
230000000770 proinflammatory effect Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 5
101150022344 BDKRB2 gene Proteins 0.000 description 5
101100178679 Caenorhabditis elegans hsp-1 gene Proteins 0.000 description 5
208000000094 Chronic Pain Diseases 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
102000004310 Ion Channels Human genes 0.000 description 5
108090000862 Ion Channels Proteins 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
102000011180 Ternary Complex Factors Human genes 0.000 description 5
108010023190 Ternary Complex Factors Proteins 0.000 description 5
230000003993 interaction Effects 0.000 description 5
125000005647 linker group Chemical group 0.000 description 5
101150099358 pain gene Proteins 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
125000001424 substituent group Chemical group 0.000 description 5
208000011580 syndromic disease Diseases 0.000 description 5
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
101150087728 Grm5 gene Proteins 0.000 description 4
101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 4
101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 4
206010065390 Inflammatory pain Diseases 0.000 description 4
108010052285 Membrane Proteins Proteins 0.000 description 4
150000001204 N-oxides Chemical class 0.000 description 4
108010018525 NFATC Transcription Factors Proteins 0.000 description 4
102000002673 NFATC Transcription Factors Human genes 0.000 description 4
241000288906 Primates Species 0.000 description 4
102100025373 Runt-related transcription factor 1 Human genes 0.000 description 4
102100023132 Transcription factor Jun Human genes 0.000 description 4
102100030246 Transcription factor Sp1 Human genes 0.000 description 4
101710085924 Transcription factor Sp1 Proteins 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
230000004069 differentiation Effects 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
102000007656 ets-Domain Protein Elk-1 Human genes 0.000 description 4
108010032461 ets-Domain Protein Elk-1 Proteins 0.000 description 4
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
210000003141 lower extremity Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000008050 pain signaling Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000004850 protein–protein interaction Effects 0.000 description 4
230000017854 proteolysis Effects 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000006641 stabilisation Effects 0.000 description 4
238000011105 stabilization Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
101150035467 BDNF gene Proteins 0.000 description 3
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 description 3
101150045775 Htr3a gene Proteins 0.000 description 3
108700002232 Immediate-Early Genes Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
102100027584 Protein c-Fos Human genes 0.000 description 3
238000002123 RNA extraction Methods 0.000 description 3
102000006467 TATA-Box Binding Protein Human genes 0.000 description 3
108010044281 TATA-Box Binding Protein Proteins 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
206010053552 allodynia Diseases 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940111134 coxibs Drugs 0.000 description 3
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000007547 defect Effects 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
229960005542 ethidium bromide Drugs 0.000 description 3
239000007943 implant Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000007913 intrathecal administration Methods 0.000 description 3
238000007914 intraventricular administration Methods 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
102000006240 membrane receptors Human genes 0.000 description 3
108020004084 membrane receptors Proteins 0.000 description 3
230000007996 neuronal plasticity Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
229940127240 opiate Drugs 0.000 description 3
230000037324 pain perception Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000012453 solvate Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
230000001629 suppression Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
108020005065 3' Flanking Region Proteins 0.000 description 2
XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
108020005029 5' Flanking Region Proteins 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
108010087765 Antipain Proteins 0.000 description 2
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108091012583 BCL2 Proteins 0.000 description 2
102000017915 BDKRB2 Human genes 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
206010006002 Bone pain Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010028165 GATA1 Transcription Factor Proteins 0.000 description 2
102000016669 GATA1 Transcription Factor Human genes 0.000 description 2
102100027346 GTP cyclohydrolase 1 Human genes 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
102000017679 HTR3A Human genes 0.000 description 2
102100032606 Heat shock factor protein 1 Human genes 0.000 description 2
102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 2
101000761343 Homo sapiens 5-hydroxytryptamine receptor 3A Proteins 0.000 description 2
101000695703 Homo sapiens B2 bradykinin receptor Proteins 0.000 description 2
101000855516 Homo sapiens Cyclic AMP-responsive element-binding protein 1 Proteins 0.000 description 2
101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 description 2
101000867525 Homo sapiens Heat shock factor protein 1 Proteins 0.000 description 2
101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 2
101001000780 Homo sapiens POU domain, class 2, transcription factor 1 Proteins 0.000 description 2
101001123678 Homo sapiens Phenylethanolamine N-methyltransferase Proteins 0.000 description 2
101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 2
101000671637 Homo sapiens Upstream stimulatory factor 1 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
208000000112 Myalgia Diseases 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 2
102100022397 Nitric oxide synthase, brain Human genes 0.000 description 2
102000007999 Nuclear Proteins Human genes 0.000 description 2
108010089610 Nuclear Proteins Proteins 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108091093037 Peptide nucleic acid Proteins 0.000 description 2
241000009328 Perro Species 0.000 description 2
102100024611 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
108010049420 RE1-silencing transcription factor Proteins 0.000 description 2
108010044012 STAT1 Transcription Factor Proteins 0.000 description 2
102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
101710144562 Transcription factor mef2A Proteins 0.000 description 2
239000007984 Tris EDTA buffer Substances 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
239000000872 buffer Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
235000021186 dishes Nutrition 0.000 description 2
239000000975 dye Substances 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
230000004927 fusion Effects 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000002045 lasting effect Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
208000013465 muscle pain Diseases 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
230000035807 sensation Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
VSEGOVBQWHSSLT-YYWUANBLSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;2-benzhydryloxy-n,n-dimethylethanamine;n-(4-hydroxyphenyl)acetamide;phosphoric acid;1,3,7-trimethylpurine-2,6-dione;hydrochloride Chemical compound Cl.OP(O)(O)=O.CC(=O)NC1=CC=C(O)C=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC VSEGOVBQWHSSLT-YYWUANBLSA-N 0.000 description 1
WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 1
SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
101150096316 5 gene Proteins 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
108010005254 Activating Transcription Factors Proteins 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
101100121721 Arabidopsis thaliana GGH1 gene Proteins 0.000 description 1
101100121722 Arabidopsis thaliana GGH2 gene Proteins 0.000 description 1
101000719121 Arabidopsis thaliana Protein MEI2-like 1 Proteins 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
101150017888 Bcl2 gene Proteins 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
102000014819 CACNA1B Human genes 0.000 description 1
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 1
108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 description 1
101150114117 EGR1 gene Proteins 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
102100021717 Early growth response protein 3 Human genes 0.000 description 1
102100021720 Early growth response protein 4 Human genes 0.000 description 1
241000792859 Enema Species 0.000 description 1
101150031329 Ets1 gene Proteins 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
102100034049 Heat shock factor protein 2 Human genes 0.000 description 1
108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 description 1
101000896450 Homo sapiens Early growth response protein 3 Proteins 0.000 description 1
101000896533 Homo sapiens Early growth response protein 4 Proteins 0.000 description 1
101001072655 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit A, mitochondrial Proteins 0.000 description 1
101001016883 Homo sapiens Heat shock factor protein 2 Proteins 0.000 description 1
101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 1
101001011393 Homo sapiens Interferon regulatory factor 2 Proteins 0.000 description 1
101001071437 Homo sapiens Metabotropic glutamate receptor 1 Proteins 0.000 description 1
101000614332 Homo sapiens P2X purinoceptor 3 Proteins 0.000 description 1
101001000773 Homo sapiens POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
101000605403 Homo sapiens Plasminogen Proteins 0.000 description 1
101000857677 Homo sapiens Runt-related transcription factor 1 Proteins 0.000 description 1
101000671649 Homo sapiens Upstream stimulatory factor 2 Proteins 0.000 description 1
101000935123 Homo sapiens Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102000004289 Interferon regulatory factor 1 Human genes 0.000 description 1
108090000890 Interferon regulatory factor 1 Proteins 0.000 description 1
102100036981 Interferon regulatory factor 1 Human genes 0.000 description 1
102100029838 Interferon regulatory factor 2 Human genes 0.000 description 1
208000018650 Intervertebral disc disease Diseases 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
208000008930 Low Back Pain Diseases 0.000 description 1
230000037364 MAPK/ERK pathway Effects 0.000 description 1
108010020933 MafG Transcription Factor Proteins 0.000 description 1
102000008610 MafG Transcription Factor Human genes 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 description 1
TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108020004485 Nonsense Codon Proteins 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
101150083523 P2RX3 gene Proteins 0.000 description 1
102100040460 P2X purinoceptor 3 Human genes 0.000 description 1
102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
102100029812 Protein S100-A12 Human genes 0.000 description 1
108010014651 Proto-Oncogene Protein c-ets-1 Proteins 0.000 description 1
102000017012 Proto-Oncogene Protein c-ets-1 Human genes 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010038678 Respiratory depression Diseases 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
108010062740 TRPV Cation Channels Proteins 0.000 description 1
102000003566 TRPV1 Human genes 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
102100039188 Transcription factor MafG Human genes 0.000 description 1
108050004005 Transcription factor MafG Proteins 0.000 description 1
102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
101150016206 Trpv1 gene Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102100040103 Upstream stimulatory factor 2 Human genes 0.000 description 1
102000040856 WT1 Human genes 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000036982 action potential Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910001413 alkali metal ion Inorganic materials 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
229940064804 betadine Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
238000010805 cDNA synthesis kit Methods 0.000 description 1
230000028956 calcium-mediated signaling Effects 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000007248 cellular mechanism Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
230000006735 deficit Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
150000002085 enols Chemical group 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
229960002737 fructose Drugs 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
238000005734 heterodimerization reaction Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000035990 intercellular signaling Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004571 lime Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000027928 long-term synaptic potentiation Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000003580 lung surfactant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000009456 molecular mechanism Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
229940053128 nerve growth factor Drugs 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
208000021722 neuropathic pain Diseases 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
210000000929 nociceptor Anatomy 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
230000037434 nonsense mutation Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
229940124583 pain medication Drugs 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
230000008447 perception Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
238000004634 pharmacological analysis method Methods 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
210000002243 primary neuron Anatomy 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000007398 protein translocation Effects 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000036280 sedation Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
238000010583 slow cooling Methods 0.000 description 1
238000011172 small scale experimental method Methods 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003568 thioethers Chemical class 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

ES08755344.2T 2007-05-11 2008-05-12 Expresión génica y dolor Active ES2542511T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US91758307P	2007-05-11	2007-05-11
US917583P		2007-05-11
PCT/US2008/063471 WO2008141308A2 (en)	2007-05-11	2008-05-12	Gene expression and pain

Publications (1)

Publication Number	Publication Date
ES2542511T3 true ES2542511T3 (es)	2015-08-06

Family

ID=40002879

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES08755344.2T Active ES2542511T3 (es)	2007-05-11	2008-05-12	Expresión génica y dolor
ES14179247.3T Active ES2619314T3 (es)	2007-05-11	2008-05-12	Expresión génica y dolor

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES14179247.3T Active ES2619314T3 (es)	2007-05-11	2008-05-12	Expresión génica y dolor

Country Status (13)

Country	Link
US (5)	US7943591B2 (2)
EP (3)	EP2818550B1 (2)
JP (5)	JP5646320B2 (2)
AU (1)	AU2008251320B2 (2)
CA (1)	CA2723672C (2)
DK (1)	DK2158316T3 (2)
ES (2)	ES2542511T3 (2)
HR (1)	HRP20150759T1 (2)
HU (1)	HUE025701T2 (2)
PL (1)	PL2158316T3 (2)
PT (1)	PT2158316E (2)
SI (1)	SI2158316T1 (2)
WO (1)	WO2008141308A2 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7943591B2 (en) *	2007-05-11	2011-05-17	Adynxx, Inc.	Gene expression and pain
CN102282155B (zh)	2008-12-02	2017-06-09	日本波涛生命科学公司	磷原子修饰的核酸的合成方法
RU2612521C2 (ru)	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
US8609617B2 (en)	2009-09-04	2013-12-17	University Of Miami	KLF family members regulate intrinsic axon regeneration ability
JP5868324B2 (ja)	2010-09-24	2016-02-24	株式会社Wave Life Sciences Japan	不斉補助基
CN103796657B (zh)	2011-07-19	2017-07-11	波涛生命科学有限公司	合成官能化核酸的方法
CA2848740A1 (en)	2011-09-16	2013-03-21	Mingxing Wang	Amphiphilic cationic polymers for the delivery of therapeutic agents
US9139829B2 (en) *	2012-02-28	2015-09-22	Medical Diagnostic Laboratories, Llc	SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
PT2846839T (pt) *	2012-05-10	2019-05-29	Adynxx Inc	Formulações para a administração de ingredientes ativos
PL2872485T3 (pl)	2012-07-13	2021-05-31	Wave Life Sciences Ltd.	Asymetryczna grupa pomocnicza
CA2879066C (en)	2012-07-13	2019-08-13	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant
KR102213609B1 (ko)	2012-07-13	2021-02-08	웨이브 라이프 사이언시스 리미티드	키랄 제어
GB201310853D0 (en) *	2013-06-18	2013-07-31	Ucb Pharma Sa	Method
JPWO2015108047A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
US10322173B2 (en)	2014-01-15	2019-06-18	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
BR112016016400A2 (pt)	2014-01-16	2017-10-03	Wave Life Sciences Ltd	Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
RU2017108238A (ru) *	2014-08-15	2018-09-17	Эйдинкс, Инк.	Олигонуклеотиды-приманки для лечения боли
ES2912176T3 (es) *	2015-09-09	2022-05-24	Anges Inc	Señuelo quimérico
WO2017151644A1 (en) *	2016-02-29	2017-09-08	Adynxx, Inc.	Compositions and methods for pain amelioration via modification of gene expression
WO2024044770A1 (en) *	2022-08-26	2024-02-29	Core Biotherapeutics, Inc.	Oligonucleotides for the treatment of breast cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6410516B1 (en)	1986-01-09	2002-06-25	President & Fellows Of Harvard College	Nuclear factors associated with transcriptional regulation
US5206152A (en)	1988-04-08	1993-04-27	Arch Development Corporation	Cloning and expression of early growth regulatory protein genes
DE3815221C2 (de)	1988-05-04	1995-06-29	Gradinger F Hermes Pharma	Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5272056A (en)	1991-01-03	1993-12-21	The Research Foundation Of State University Of New York	Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
CA2106386A1 (en)	1991-04-18	1992-10-19	Barbara C. F. Chu	Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr)	1991-04-25	1996-09-06	Genset Sa	Oligonucleotides fermes, antisens et sens et leurs applications.
EP0771320A4 (en)	1993-07-29	1998-11-25	Univ California	POLYNUCLEOTIDE LURES INHIBITING THE EXPRESSION OF MAJOR II HISTOCOMPATIBILITY COMPLEX, AND APPLICATIONS
PT732929E (pt)	1993-10-29	2008-08-26	Brigham & Womens Hospital	Utilização terapêutica de ''engodos'' de elementos cis in vivo
AU3881095A (en)	1994-11-17	1996-06-17	Taiho Pharmaceutical Co., Ltd.	Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
WO1996029433A1 (en)	1995-03-23	1996-09-26	Research Foundation Of State University Of New York	Rest protein and dna
ATE271128T1 (de)	1995-05-11	2004-07-15	Applied Research Systems	Inhibitoren der il-6 aktivitaet
ES2285712T3 (es)	1995-05-12	2007-11-16	Anges Mg, Inc.	Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
GB9515356D0 (en)	1995-07-26	1995-09-20	Medical Res Council	Improvements in or relating to delivery of nucleic acid
US6265389B1 (en)	1995-08-31	2001-07-24	Alkermes Controlled Therapeutics, Inc.	Microencapsulation and sustained release of oligonucleotides
EP1011729B1 (en)	1996-05-20	2008-01-09	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligonucleotides which specifically bind retroviral nucleocapsid proteins
US6022863A (en)	1996-05-21	2000-02-08	Yale University	Regulation of gene expression
US6890909B1 (en)	1997-07-04	2005-05-10	Fujisawa Pharmaceutical Co., Ltd.	Brain-protective agent
JP3667047B2 (ja)	1997-09-12	2005-07-06	キヤノン株式会社	人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
US6376471B1 (en)	1997-10-10	2002-04-23	Johns Hopkins University	Gene delivery compositions and methods
US6060310A (en)	1997-11-24	2000-05-09	The United States Of America As Represented By The Department Of Health And Human Services	Transcription factor decoy and tumor growth inhibitor
AU1656299A (en)	1997-12-16	1999-07-05	University Of Saskatchewan	Conductive metal-containing nucleic acids
IL139936A0 (en)	1998-06-02	2002-02-10	Glaxo Group Ltd	Gene therapy method
US6818626B1 (en)	1998-07-17	2004-11-16	Mirus Corporation	Chelating systems for use in the delivery of compounds to cells
US6423493B1 (en)	1998-10-26	2002-07-23	Board Of Regents The University Of Texas System	Combinatorial selection of oligonucleotide aptamers
US6008048A (en)	1998-12-04	1999-12-28	Isis Pharmaceuticals Inc.	Antisense inhibition of EGR-1 expression
US7160869B2 (en)	1998-12-16	2007-01-09	University Of Saskatchewan	Biologically active metal-containing nucleic acids
IL143734A0 (en)	1998-12-23	2002-04-21	Genentech Inc	Transfectacons comprising calcium phosphate and a nucleic acid
US6395029B1 (en)	1999-01-19	2002-05-28	The Children's Hospital Of Philadelphia	Sustained delivery of polyionic bioactive agents
US6333408B1 (en)	1999-03-08	2001-12-25	Kureha Chemical Industry Co., Ltd.	Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr)	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
CA2300328A1 (en)	1999-09-14	2001-03-14	Cardiogene Gentherap. Systeme Ag	Modulating transcription of genes in vascular cells
US6927027B2 (en)	1999-12-21	2005-08-09	Ingeneus Corporation	Nucleic acid multiplex formation
US6969704B1 (en)	2000-08-25	2005-11-29	The Trustees Of Columbia University In The City Of New York	Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
DE10049549A1 (de)	2000-10-06	2002-05-02	Markus Hecker	Modulation der Transkription pro-inflammatorischer Genprodukte
US20040192598A1 (en)	2000-10-11	2004-09-30	Laura Kragie	Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
EP1344536A4 (en)	2000-11-24	2005-01-19	Chugai Pharmaceutical Co Ltd	METHOD FOR REGULATING THE EFFECT OF THE EXPRESSION PRODUCT OF A GENE TRANSFERRED IN A LIVING BODY
US20020137715A1 (en)	2001-01-03	2002-09-26	Alain Mauviel	Blocking Sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis
US7060690B2 (en)	2001-01-22	2006-06-13	Genta Incorporated	Methods and compositions for treating a cell-proliferative disorder using CRE decoy oligomers, BCL-2 antisense oligomers, and hybrid oligomers thereof
EP1362600B1 (en)	2001-02-20	2008-04-02	AnGes MG, Inc.	TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
US20070122401A1 (en)	2001-03-06	2007-05-31	Andrews William H	Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en)	2001-04-02	2003-09-04	Alberini Cristina M.	Methods and compositions for regulating memory consolidation
EP1298141A1 (en)	2001-09-27	2003-04-02	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
DE10148828B4 (de)	2001-10-04	2005-05-19	Avontec Gmbh	Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en)	2001-11-30	2003-12-16	Advanced Cardiovascular Systems, Inc.	Permeabilizing reagents to increase drug delivery and a method of local delivery
CN1697647A (zh)	2002-02-01	2005-11-16	奥默罗斯公司	用于抑制疼痛,炎症和软骨退化的溶液及方法
CN1240439C (zh)	2002-03-28	2006-02-08	南京凯基生物科技发展有限公司	肿瘤基因开关药物
US20070014840A1 (en)	2002-04-26	2007-01-18	In-Kyu Lee	Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
DE10242319A1 (de)	2002-09-12	2004-03-25	Avontec Gmbh	Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
DE10257421A1 (de)	2002-12-09	2004-07-08	Grünenthal GmbH	Regulatorische Elemente im 5'-Bereich des VR1-Gens
KR20120068035A (ko)	2002-12-09	2012-06-26	아브락시스 바이오사이언스, 엘엘씨	약리학적 물질의 조성물 및 그 전달방법
EP1644532A4 (en)	2003-06-30	2007-11-28	Massachusetts Inst Technology	EGR GENES AS OBJECTIVES FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA
WO2005027830A2 (en) *	2003-09-12	2005-03-31	Virginia Commonwealth University	Chimeric transcription factor decoy oligonucleotides
JP2005336081A (ja)	2004-05-26	2005-12-08	Anges Mg Inc	Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en)	2004-07-01	2009-01-27	Mathison Brian H	Composite polynucleic acid therapeutics
WO2006012625A2 (en)	2004-07-22	2006-02-02	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Stat3 decoy oligonucleotides and uses therefor
AU2005286640A1 (en)	2004-09-21	2006-03-30	Anesiva, Inc.	Delivery of polynucleotides
AU2005288522B2 (en)	2004-09-28	2012-06-28	Quark Pharmaceuticals, Inc.	Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US8067384B2 (en) *	2004-10-22	2011-11-29	Anges Mg, Inc.	Chimera (double) decoy
US7585848B2 (en) *	2005-01-11	2009-09-08	Rush University Medical Center	Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
WO2006096498A2 (en) *	2005-03-04	2006-09-14	Dana-Farber Cancer Institute, Inc.	Regulation of runx1 for treatment of pain
US7680060B2 (en) *	2005-03-08	2010-03-16	Cisco Technology, Inc.	Transferring state information in a network
EP1877556B1 (en)	2005-03-25	2011-09-14	Medtronic, Inc.	Use of anti-tnf or anti-il1 rnai to suppress pro- inflammatory cytokine actions locally to treat pain
EP2086573B1 (en)	2006-10-09	2020-11-25	Neurofluidics, Inc.	Cerebrospinal fluid purification system
CN101686939B (zh)	2007-04-17	2013-03-27	巴克斯特国际公司	用于肺部投送的核酸微粒
US7943591B2 (en)	2007-05-11	2011-05-17	Adynxx, Inc.	Gene expression and pain
BR112013003875B1 (pt)	2010-08-20	2021-10-05	Replicor Inc	Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
US20140275211A1 (en)	2011-06-21	2014-09-18	Alnylam Pharmaceuticals, Inc.	Assays and methods for determining activity of a therapeutic agent in a subject
EP2734212B1 (en)	2011-07-20	2017-09-06	Hospira, Inc.	Compositions comprising diclofenac for the treatment of post-operative pain
PT2846839T (pt)	2012-05-10	2019-05-29	Adynxx Inc	Formulações para a administração de ingredientes ativos
SMT202100319T1 (it)	2012-05-18	2021-09-14	Replicor Inc	Composizioni e metodi del complesso oligonucleotide chelato polipeptidico
RU2017108238A (ru)	2014-08-15	2018-09-17	Эйдинкс, Инк.	Олигонуклеотиды-приманки для лечения боли
WO2017151644A1 (en)	2016-02-29	2017-09-08	Adynxx, Inc.	Compositions and methods for pain amelioration via modification of gene expression

2008
- 2008-05-12 US US12/119,435 patent/US7943591B2/en not_active Expired - Fee Related
- 2008-05-12 WO PCT/US2008/063471 patent/WO2008141308A2/en not_active Ceased
- 2008-05-12 EP EP14179247.3A patent/EP2818550B1/en not_active Not-in-force
- 2008-05-12 CA CA2723672A patent/CA2723672C/en active Active
- 2008-05-12 EP EP08755344.2A patent/EP2158316B1/en not_active Not-in-force
- 2008-05-12 HR HRP20150759TT patent/HRP20150759T1/hr unknown
- 2008-05-12 AU AU2008251320A patent/AU2008251320B2/en not_active Ceased
- 2008-05-12 PT PT87553442T patent/PT2158316E/pt unknown
- 2008-05-12 SI SI200831461T patent/SI2158316T1/sl unknown
- 2008-05-12 PL PL08755344T patent/PL2158316T3/pl unknown
- 2008-05-12 DK DK08755344.2T patent/DK2158316T3/en active
- 2008-05-12 EP EP16199871.1A patent/EP3199635B1/en not_active Not-in-force
- 2008-05-12 JP JP2010507728A patent/JP5646320B2/ja not_active Expired - Fee Related
- 2008-05-12 HU HUE08755344A patent/HUE025701T2/en unknown
- 2008-05-12 ES ES08755344.2T patent/ES2542511T3/es active Active
- 2008-05-12 ES ES14179247.3T patent/ES2619314T3/es active Active
2011
- 2011-03-15 US US13/048,793 patent/US8093225B2/en not_active Expired - Fee Related
- 2011-12-09 US US13/316,321 patent/US8741864B2/en active Active - Reinstated
2014
- 2014-04-22 US US14/258,927 patent/US9290762B2/en not_active Expired - Fee Related
- 2014-07-23 JP JP2014149516A patent/JP5890869B2/ja not_active Expired - Fee Related
2015
- 2015-10-22 JP JP2015207655A patent/JP6082796B2/ja not_active Expired - Fee Related
2016
- 2016-02-09 US US15/019,791 patent/US10041069B2/en active Active
- 2016-03-28 JP JP2016064037A patent/JP6306075B2/ja not_active Expired - Fee Related
2017
- 2017-05-30 JP JP2017106521A patent/JP2017148074A/ja active Pending

Also Published As

Publication number	Publication date
EP3199635A1 (en)	2017-08-02
US10041069B2 (en)	2018-08-07
US20140343132A1 (en)	2014-11-20
HUE025701T2 (en)	2016-04-28
US9290762B2 (en)	2016-03-22
JP6082796B2 (ja)	2017-02-15
JP2017148074A (ja)	2017-08-31
ES2619314T3 (es)	2017-06-26
EP2158316B1 (en)	2015-04-15
US8093225B2 (en)	2012-01-10
HK1205530A1 (en)	2015-12-18
HRP20150759T1 (hr)	2015-08-14
EP2818550B1 (en)	2016-12-28
EP2818550A1 (en)	2014-12-31
US20080300209A1 (en)	2008-12-04
CA2723672A1 (en)	2008-11-20
JP2014198053A (ja)	2014-10-23
PL2158316T3 (pl)	2015-10-30
JP2010526541A (ja)	2010-08-05
EP2158316A4 (en)	2011-11-09
EP3199635B1 (en)	2019-02-06
US20110166212A1 (en)	2011-07-07
WO2008141308A2 (en)	2008-11-20
CA2723672C (en)	2019-09-03
AU2008251320B2 (en)	2013-12-19
US20120232131A1 (en)	2012-09-13
US20160222382A1 (en)	2016-08-04
EP2158316A2 (en)	2010-03-03
JP2016014070A (ja)	2016-01-28
JP5890869B2 (ja)	2016-03-22
US7943591B2 (en)	2011-05-17
SI2158316T1 (sl)	2015-08-31
AU2008251320A1 (en)	2008-11-20
PT2158316E (pt)	2015-07-20
DK2158316T3 (en)	2015-07-20
JP2016117775A (ja)	2016-06-30
US8741864B2 (en)	2014-06-03
JP6306075B2 (ja)	2018-04-04
JP5646320B2 (ja)	2014-12-24
WO2008141308A3 (en)	2009-03-05

Publication	Publication Date	Title
ES2542511T3 (es)	2015-08-06	Expresión génica y dolor
EA022429B1 (ru)	2015-12-30	АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
ES3049432T3 (en)	2025-12-16	Indazole derivatives as inhibitors of sarm1
ES2901772T3 (es)	2022-03-23	Conjugados de péptido oligonucleótido
JP6705807B2 (ja)	2020-06-03	疼痛を治療するためのオリゴヌクレオチドデコイ
RU2668136C2 (ru)	2018-09-26	Композиции для доставки активных ингредиентов
AU2014201462B2 (en)	2016-09-29	Gene expression and pain
AU2016266076B2 (en)	2018-08-30	Gene expression and pain
ES2312192T3 (es)	2009-02-16	Uso de oligomeros de acidos nucleicos de poliamida para engendrar una respuesta biologica.
US20240287519A1 (en)	2024-08-29	Treatment of dkk2 related diseases and disorders
HK1205530B (en)	2018-02-15	Gene expression and pain
URACIL-BASED	2005	SYNTHESIS AND THREE-DIMENSIONAL QUANTITATIVE STRUCTURE